Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
AL Sydbank delivers strong first financial statements
-
Novonesis delivered strong organic sales growth of 7% in 2025
-
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
-
Twelve months 2025 interim report
-
Ethris Part of Consortium to Receive up to EUR 148 Million European Commission Contract to Advance Novel Pandemic Influenza Vaccine
-
PRESS RELEASE: Nacon announces that it has today filed for insolvency and is requesting the initiation of judicial reorganisation proceedings
-
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
-
VINCI launches an issue of bonds exchangeable for existing ordinary shares of Groupe ADP due 2031 for a nominal amount of €500m
-
2026 Production and Financial Guidance and Exploration Update
-
PRESS RELEASE: Bigben Interactive announces that it is today requesting the initiation of an amicable conciliation procedure in order to facilitate discussions with its financial creditors
-
Ignitis Group has agreed to sell 49% of its shares in Vilnius CHP
-
Wolters Kluwer 2025 Full-Year Report
-
NBPE Announces Transaction in Own Shares
-
AKVA group ASA: New land-based RAS contract signed
-
Statkraft signs contract with OX2 to optimize large-scale batteries in Finland
-
OSB GROUP PLC - Transaction in Own Shares
-
Aktsiaselts Infortar Unaudited Consolidated Interim Report for fourth quarter and 12 months of 2025
-
Aspocomp’s Financial Statement Release 2025: Net sales increased significantly, and the operating result turned profitable
-
Transaction in Own Shares
-
STMicroelectronics President and CEO Jean-Marc Chery to speak at Morgan Stanley investor conference
-
Facephi Enters the Japanese Identity and Fraud-Prevention Market via Hancom
-
94 new customers
-
Novonesis' Annual Report 2025
-
Outlook for 2026 and new share buyback
-
Notice convening the Annual General Meeting
-
BUREAU VERITAS - Sector-leading organic revenue growth of 6.5% in FY 2025, strong margin improvement to 16.3% in FY 2025, positive growth outlook with continued margin expansion in 2026 and new EUR 20
-
WORLDLINE : strategic sale of its Indian payment activities to BillDesk - Press release
-
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
-
Ageas reports full-year 2025 results
-
NORBIT – Advanced negotiations regarding a NOK 115 million contract
-
Vopak announces a multi-year share buyback program of up to EUR 500 million and commences the first tranche of up to EUR 100 million
-
TextMagic AS 2025 12 months consolidated unaudited interim report
-
ASML publishes 2025 Annual Reports
-
Start of Day Message
-
Vow ASA: Record Q4 revenues and strategy revision concluded
-
KALDVIK AS (KLDVK): Q4 2025 Quarterly Update
-
Bigbank AS Results for January 2026
-
Vopak reports record financial results for 2025 and announces shareholder distributions program of around EUR 1.7 billion through year-end 2030
-
Martela Corporation’s Financial Statements 1 January – 31 December 2025
-
Navatar Launches AI-Powered CRM Operating Model On Salesforce for Alternative Asset Managers
-
FLSmidth: Transactions under share buy-back programme
-
Abbott Cooper PLLC Investigates Potential Breaches of Fiduciary Duty by MarketWise, Inc. Board of Directors
-
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
-
Abbott Cooper PLLC Investigates Potential Breaches of Fiduciary Duty by Lee Enterprises, Incorporated Board of Directors
-
Intuitive Machines Announces Date for Fourth Quarter, Full-Year 2025 Financial Results, and Post-Lanteris Space Systems Acquisition Conference Call
-
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
Next Point Advises Endodontic Specialties of NEPA on Practice Transition
-
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
